AR070027A1 - Agentes anti-infecciosos contra el virus hcv - Google Patents
Agentes anti-infecciosos contra el virus hcvInfo
- Publication number
- AR070027A1 AR070027A1 ARP080104045A ARP080104045A AR070027A1 AR 070027 A1 AR070027 A1 AR 070027A1 AR P080104045 A ARP080104045 A AR P080104045A AR P080104045 A ARP080104045 A AR P080104045A AR 070027 A1 AR070027 A1 AR 070027A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- amino
- independently selected
- heterocyclyl
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 2
- 229960005475 antiinfective agent Drugs 0.000 title 1
- 239000004599 antimicrobial Substances 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 28
- 125000000217 alkyl group Chemical group 0.000 abstract 20
- 125000000623 heterocyclic group Chemical group 0.000 abstract 20
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 18
- -1 hydroxy, methyl Chemical group 0.000 abstract 18
- 125000003342 alkenyl group Chemical group 0.000 abstract 17
- 125000000304 alkynyl group Chemical group 0.000 abstract 17
- 125000001475 halogen functional group Chemical group 0.000 abstract 15
- 125000003545 alkoxy group Chemical group 0.000 abstract 14
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 13
- 125000004043 oxo group Chemical group O=* 0.000 abstract 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 11
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 9
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 9
- 150000001875 compounds Chemical class 0.000 abstract 8
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 5
- 125000005193 alkenylcarbonyloxy group Chemical group 0.000 abstract 4
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 abstract 4
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 4
- 125000005198 alkynylcarbonyloxy group Chemical group 0.000 abstract 4
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 abstract 4
- 125000005884 carbocyclylalkyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 abstract 3
- 125000005090 alkenylcarbonyl group Chemical group 0.000 abstract 3
- 125000005137 alkenylsulfonyl group Chemical group 0.000 abstract 3
- 125000005087 alkynylcarbonyl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 abstract 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005139 alkynylsulfonyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 abstract 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 abstract 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 125000005280 halo alkyl sulfonyloxy group Chemical group 0.000 abstract 1
- 230000001553 hepatotropic effect Effects 0.000 abstract 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97287707P | 2007-09-17 | 2007-09-17 | |
| US9679108P | 2008-09-13 | 2008-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070027A1 true AR070027A1 (es) | 2010-03-10 |
Family
ID=39948002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104045A AR070027A1 (es) | 2007-09-17 | 2008-09-17 | Agentes anti-infecciosos contra el virus hcv |
| ARP120102873A AR087472A2 (es) | 2007-09-17 | 2012-08-06 | Agentes anti-infecciosos y su uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102873A AR087472A2 (es) | 2007-09-17 | 2012-08-06 | Agentes anti-infecciosos y su uso |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8415351B2 (show.php) |
| EP (2) | EP2725015A1 (show.php) |
| JP (2) | JP5734654B2 (show.php) |
| KR (2) | KR101552474B1 (show.php) |
| CN (2) | CN101801935B (show.php) |
| AR (2) | AR070027A1 (show.php) |
| AU (1) | AU2008302448B2 (show.php) |
| BR (1) | BRPI0816994B8 (show.php) |
| CA (2) | CA2976793A1 (show.php) |
| CL (2) | CL2008002794A1 (show.php) |
| CO (1) | CO6260076A2 (show.php) |
| CR (2) | CR11316A (show.php) |
| DO (2) | DOP2010000084A (show.php) |
| ES (1) | ES2453591T3 (show.php) |
| GT (1) | GT201000061A (show.php) |
| IL (1) | IL204547A (show.php) |
| IN (1) | IN2012DN05113A (show.php) |
| MX (2) | MX2010002905A (show.php) |
| MY (1) | MY162760A (show.php) |
| NZ (3) | NZ600371A (show.php) |
| PA (1) | PA8796201A1 (show.php) |
| PE (2) | PE20130209A1 (show.php) |
| PH (1) | PH12013500365A1 (show.php) |
| RU (2) | RU2543620C2 (show.php) |
| SG (1) | SG183733A1 (show.php) |
| TW (2) | TWI534137B (show.php) |
| UA (1) | UA117800C2 (show.php) |
| UY (1) | UY31344A1 (show.php) |
| WO (1) | WO2009039127A1 (show.php) |
| ZA (2) | ZA201204224B (show.php) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2203431B1 (en) * | 2007-09-17 | 2011-08-10 | Abbott Laboratories | Anti-infective pyrimidines and uses thereof |
| DK2203430T3 (da) | 2007-09-17 | 2011-09-26 | Abbott Lab | N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV) |
| SG183733A1 (en) | 2007-09-17 | 2012-09-27 | Abbott Lab | Uracil or thymine derivative for treating hepatitis c |
| JP5249344B2 (ja) * | 2007-11-16 | 2013-07-31 | メルク・シャープ・アンド・ドーム・コーポレーション | ヘテロ環の３位が置換されたインドール誘導体およびその使用 |
| JP2011528686A (ja) | 2008-07-23 | 2011-11-24 | エフ．ホフマン−ラ ロシュ アーゲー | ヘテロ環式抗ウイルス性化合物 |
| JP2012503620A (ja) | 2008-09-26 | 2012-02-09 | エフ．ホフマン−ラ ロシュ アーゲー | Ｈｃｖを処置するためのピリンまたはピラジン誘導体 |
| BRPI1009854A2 (pt) * | 2009-03-24 | 2015-08-25 | Abbott Lab | Processo para preparar composto antiviral |
| EP2421845B1 (en) * | 2009-03-25 | 2013-04-17 | Abbott Laboratories | Antiviral compounds and uses thereof |
| US20120065247A1 (en) * | 2009-03-27 | 2012-03-15 | Discoverybiomed, Inc. | Modulating ires-mediated translation |
| JP2012524752A (ja) | 2009-04-25 | 2012-10-18 | エフ．ホフマン−ラ ロシュ アーゲー | 複素環式抗ウイルス化合物 |
| TWI428332B (zh) | 2009-06-09 | 2014-03-01 | Hoffmann La Roche | 雜環抗病毒化合物 |
| EP2445875A2 (en) * | 2009-06-24 | 2012-05-02 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compound |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| CN102498100A (zh) | 2009-09-21 | 2012-06-13 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒杂环化合物 |
| MX2012005706A (es) * | 2009-11-21 | 2012-06-12 | Hoffmann La Roche | Compuestos antivirales heterociclicos. |
| AR079440A1 (es) | 2009-12-14 | 2012-01-25 | Hoffmann La Roche | Compuestos heterociclicos antivirales |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| RU2572558C2 (ru) | 2010-07-07 | 2016-01-20 | Ф. Хоффманн-Ля Рош Аг | Противовирусные гетероциклические соединения |
| AU2015201698B2 (en) * | 2010-07-16 | 2017-02-02 | Abbvie Ireland Unlimited Company | Process for preparing antiviral compounds |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| KR101774742B1 (ko) | 2010-07-16 | 2017-09-11 | 애브비 아일랜드 언리미티드 컴퍼니 | 촉매 반응용 포스핀 리간드 |
| EP3415504A1 (en) | 2010-07-16 | 2018-12-19 | AbbVie Ireland Unlimited Company | Process for preparing antiviral compounds |
| RU2436786C1 (ru) * | 2010-07-23 | 2011-12-20 | Александр Васильевич Иващенко | Замещенные индолы, противовирусный активный компонент, способ получения и применения |
| WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体 |
| MX2013001273A (es) | 2010-08-13 | 2013-04-10 | Hoffmann La Roche | Compuestos heterociclicos antivirales. |
| CN102675092B (zh) * | 2011-03-14 | 2014-11-05 | 江苏中丹药物研究有限公司 | 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法 |
| TWI558400B (zh) | 2011-03-18 | 2016-11-21 | 艾伯維有限公司 | 苯基尿嘧啶化合物之調配物 |
| US20140065223A1 (en) * | 2011-03-31 | 2014-03-06 | Jeanette Libera-Koerner | Perfluorinated compounds for the non-viral transfer of nucleic acids |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| JP5734124B2 (ja) * | 2011-07-21 | 2015-06-10 | 株式会社 東邦アーステック | １，３−ジヨードヒダントイン類の製造方法 |
| US9040516B2 (en) | 2011-08-01 | 2015-05-26 | Sumitomo Dainippon Pharma Co., Ltd. | Uracil derivative and use thereof for medical purposes |
| AU2015200715A1 (en) * | 2011-10-21 | 2015-03-05 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| SE1450130A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon |
| SE1450131A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV |
| JP6078640B2 (ja) | 2012-05-15 | 2017-02-08 | ノバルティス アーゲー | Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体 |
| WO2013171641A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| KR102091893B1 (ko) | 2012-05-15 | 2020-03-23 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
| JP6204975B2 (ja) | 2012-05-15 | 2017-09-27 | ノバルティス アーゲー | Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体 |
| EP2866807A2 (en) | 2012-06-27 | 2015-05-06 | Abbvie Inc. | Methods for treating hcv |
| MX360161B (es) * | 2012-08-21 | 2018-10-09 | Abbvie Inc | Proceso para preparar compuestos antiviricos. |
| US9629841B2 (en) * | 2012-10-18 | 2017-04-25 | Abbvie Inc. | Formulations of pyrimidinedione derivative compounds |
| JP2014101316A (ja) * | 2012-11-20 | 2014-06-05 | Toyobo Co Ltd | ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法 |
| CA2916912A1 (en) | 2013-07-02 | 2015-01-08 | Abbvie Inc. | Methods for treating hcv |
| WO2015004028A1 (de) | 2013-07-08 | 2015-01-15 | Bayer Cropscience Ag | Sechsgliedrige c-n-verknüpfte arylsulfid- und arylsulfoxid- derivate als schädlingsbekämpfungsmittel |
| US10149859B2 (en) | 2013-09-11 | 2018-12-11 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| US20150209403A1 (en) | 2014-01-28 | 2015-07-30 | Abbvie Inc. | Dose Adjustment |
| HUE045511T2 (hu) | 2014-02-03 | 2020-01-28 | Vitae Pharmaceuticals Llc | A ror-gamma dihidro-pirrolopiridin inhibitorai |
| WO2015197028A1 (en) * | 2014-06-28 | 2015-12-30 | Sunshine Lake Pharma Co., Ltd. | Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine |
| WO2016004513A1 (en) * | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| US10752640B2 (en) | 2014-08-01 | 2020-08-25 | Nuevolution A/S | Compounds active towards bromodomains |
| WO2016040588A1 (en) | 2014-09-11 | 2016-03-17 | Abbvie Inc. | Treatment of hcv by administering four different anti-hcv compounds with food |
| EP3207043B3 (en) | 2014-10-14 | 2019-10-02 | Vitae Pharmaceuticals, LLC | Dihydropyrrolopyridine inhibitors of ror-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| RU2590952C1 (ru) * | 2015-05-26 | 2016-07-10 | Вячеслав Энгельсович Семёнов | Средство гепатопротекторного действия |
| WO2016196280A1 (en) | 2015-06-02 | 2016-12-08 | E I Du Pont De Nemours And Company | Heterocycle-substituted bicyclic pesticides |
| US10517870B2 (en) * | 2015-07-30 | 2019-12-31 | Bristol-Myers Squibb Company | Aryl substituted bicycle heteroaryl compounds |
| DK3331876T3 (da) | 2015-08-05 | 2021-01-11 | Vitae Pharmaceuticals Llc | Modulators of ror-gamma |
| CN108463458B (zh) | 2015-11-20 | 2022-02-01 | 生命医药有限责任公司 | ROR-γ的调节剂 |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| CN109689063A (zh) | 2016-04-28 | 2019-04-26 | 埃默里大学 | 含有炔烃的核苷酸和核苷治疗组合物及其相关用途 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| CN115716826A (zh) | 2017-07-24 | 2023-02-28 | 生命医药有限责任公司 | RORγ的抑制剂 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN107266373A (zh) * | 2017-08-01 | 2017-10-20 | 安徽拜善晟制药有限公司 | 一种原料药达沙布韦的制备方法 |
| CN118754858A (zh) | 2018-03-26 | 2024-10-11 | 诺华股份有限公司 | N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物 |
| CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
| CN114521196A (zh) * | 2019-09-16 | 2022-05-20 | 诺华股份有限公司 | 双官能团降解剂及其使用方法 |
| EP3819006A1 (en) | 2019-11-05 | 2021-05-12 | Technische Universität Dresden | Compounds with thymine skeleton for use in medicine |
| CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239888A (en) * | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JPS60243017A (ja) * | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| US5084084A (en) * | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| AU627906B2 (en) * | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| US5162326A (en) | 1990-02-15 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Pyrimidinedione derivatives, their production and use |
| NL9001075A (show.php) * | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
| EP0489480A1 (en) * | 1990-12-05 | 1992-06-10 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
| DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
| HK1054384B (zh) | 1999-12-06 | 2005-12-09 | 霍夫曼-拉罗奇有限公司 | 4-嘧啶基-n-酰基-l-苯基丙氨酸类化合物 |
| US6380387B1 (en) * | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| IL167954A (en) * | 2000-02-04 | 2007-10-31 | Sumitomo Chemical Co | History of pyrimidine |
| RU2264395C2 (ru) * | 2000-02-04 | 2005-11-20 | Сумитомо Кемикал Компани, Лимитед | Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты) |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| KR100589964B1 (ko) * | 2003-06-13 | 2006-06-19 | 주식회사 엘지생명과학 | Ｃ형 간염 바이러스의 억제제 |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| JO2934B1 (en) * | 2006-06-23 | 2015-09-15 | سميث كلاين بيتشام كوربوريشن | Prolyl hydroxylase inhibitors |
| SG183733A1 (en) * | 2007-09-17 | 2012-09-27 | Abbott Lab | Uracil or thymine derivative for treating hepatitis c |
| EP2203431B1 (en) * | 2007-09-17 | 2011-08-10 | Abbott Laboratories | Anti-infective pyrimidines and uses thereof |
| DK2203430T3 (da) | 2007-09-17 | 2011-09-26 | Abbott Lab | N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV) |
| JP2011528686A (ja) | 2008-07-23 | 2011-11-24 | エフ．ホフマン−ラ ロシュ アーゲー | ヘテロ環式抗ウイルス性化合物 |
-
2008
- 2008-09-17 SG SG2012060521A patent/SG183733A1/en unknown
- 2008-09-17 IN IN5113DEN2012 patent/IN2012DN05113A/en unknown
- 2008-09-17 UY UY31344A patent/UY31344A1/es active IP Right Grant
- 2008-09-17 ES ES08831873.8T patent/ES2453591T3/es active Active
- 2008-09-17 RU RU2010114828/04A patent/RU2543620C2/ru not_active IP Right Cessation
- 2008-09-17 KR KR1020107008431A patent/KR101552474B1/ko active Active
- 2008-09-17 TW TW103110394A patent/TWI534137B/zh not_active IP Right Cessation
- 2008-09-17 CN CN200880107764.3A patent/CN101801935B/zh not_active Expired - Fee Related
- 2008-09-17 CN CN201210157072.8A patent/CN102746239B/zh not_active Expired - Fee Related
- 2008-09-17 JP JP2010525102A patent/JP5734654B2/ja not_active Expired - Fee Related
- 2008-09-17 NZ NZ600371A patent/NZ600371A/en unknown
- 2008-09-17 KR KR1020157010052A patent/KR101660360B1/ko not_active Expired - Fee Related
- 2008-09-17 UA UAA201302816A patent/UA117800C2/uk unknown
- 2008-09-17 WO PCT/US2008/076576 patent/WO2009039127A1/en not_active Ceased
- 2008-09-17 CL CL2008002794A patent/CL2008002794A1/es unknown
- 2008-09-17 CA CA2976793A patent/CA2976793A1/en not_active Abandoned
- 2008-09-17 MY MYPI2010001141A patent/MY162760A/en unknown
- 2008-09-17 TW TW097135721A patent/TWI437994B/zh active
- 2008-09-17 CA CA2699981A patent/CA2699981C/en not_active Expired - Fee Related
- 2008-09-17 AU AU2008302448A patent/AU2008302448B2/en active Active
- 2008-09-17 MX MX2010002905A patent/MX2010002905A/es active IP Right Grant
- 2008-09-17 AR ARP080104045A patent/AR070027A1/es active IP Right Grant
- 2008-09-17 BR BRPI0816994A patent/BRPI0816994B8/pt active IP Right Grant
- 2008-09-17 EP EP13193524.9A patent/EP2725015A1/en not_active Withdrawn
- 2008-09-17 NZ NZ584720A patent/NZ584720A/en not_active IP Right Cessation
- 2008-09-17 EP EP08831873.8A patent/EP2222646B1/en not_active Not-in-force
- 2008-09-17 PA PA20088796201A patent/PA8796201A1/es unknown
- 2008-09-17 PE PE2012002073A patent/PE20130209A1/es not_active Application Discontinuation
- 2008-09-17 PE PE2008001621A patent/PE20090705A1/es active IP Right Grant
- 2008-09-17 NZ NZ618277A patent/NZ618277A/en not_active IP Right Cessation
-
2010
- 2010-03-15 GT GT201000061A patent/GT201000061A/es unknown
- 2010-03-16 DO DO2010000084A patent/DOP2010000084A/es unknown
- 2010-03-16 IL IL204547A patent/IL204547A/en active Protection Beyond IP Right Term
- 2010-03-16 MX MX2012004779A patent/MX338555B/es unknown
- 2010-03-16 CR CR11316A patent/CR11316A/es unknown
- 2010-03-16 CO CO10030957A patent/CO6260076A2/es active IP Right Grant
- 2010-03-17 US US12/725,689 patent/US8415351B2/en not_active Expired - Fee Related
- 2010-12-21 DO DO2010000396A patent/DOP2010000396A/es unknown
-
2012
- 2012-04-03 US US13/438,609 patent/US8685991B2/en not_active Expired - Fee Related
- 2012-06-08 ZA ZA2012/04224A patent/ZA201204224B/en unknown
- 2012-06-08 ZA ZA2012/04223A patent/ZA201204223B/en unknown
- 2012-08-06 AR ARP120102873A patent/AR087472A2/es unknown
- 2012-10-11 JP JP2012225875A patent/JP2013049681A/ja active Pending
-
2013
- 2013-02-01 RU RU2013104270/04A patent/RU2599635C2/ru not_active IP Right Cessation
- 2013-02-06 CL CL2013000372A patent/CL2013000372A1/es unknown
- 2013-02-25 PH PH12013500365A patent/PH12013500365A1/en unknown
-
2014
- 2014-03-31 US US14/230,965 patent/US9095590B2/en not_active Expired - Fee Related
-
2015
- 2015-05-08 CR CR20150238A patent/CR20150238A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070027A1 (es) | Agentes anti-infecciosos contra el virus hcv | |
| RU2011142978A (ru) | Противовирусные соединения и их применения | |
| JP2010539186A5 (show.php) | ||
| RU2011142979A (ru) | Противовирусные соединения и их применения | |
| JP2016506960A5 (show.php) | ||
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| HRP20110632T1 (hr) | N-fenil-diokso-hidropirimidini korisni kao inhibitori virusa hepatitisa c (hcv) | |
| AR060609A1 (es) | Compuestos inhibidores de proteinquinasas c-fms. | |
| AR069368A1 (es) | Mezclas fungicidas | |
| AR068511A1 (es) | Tetrahidro[1,4'] bipiridinil-2'-onas sustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central | |
| EA201500266A1 (ru) | Ингибиторы репликации вирусов гриппа | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| EA201391158A8 (ru) | Диаминиевые соли фенотиазина и их применение | |
| AR085354A1 (es) | Derivados de isoxazol para control de pestes invertebrados | |
| TN2014000243A1 (fr) | Benzopyrannes nouveaux, compositions les contenant et leurs utilisations | |
| AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
| JP2014530900A5 (show.php) | ||
| AR056964A1 (es) | Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos | |
| AR074801A1 (es) | Monocarbamas y composiciones farmaceuticas que los contienen | |
| AR065804A1 (es) | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento | |
| AR076412A1 (es) | Compuestos diamida que tienen actividad antagonista de receptores muscarinicos y agonista del receptor adrenergico (beta)2 | |
| EA200801828A3 (ru) | Соединения 1,2,4,5- тетрагидро-3н-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения | |
| AR102939A1 (es) | 3-oxo-3-(arilamino)propanoatos, proceso para prepararlos, y su uso para preparar pirrolidinonas | |
| BRPI0607015A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto | |
| EA201200189A1 (ru) | Фуразанобензимидазолы в качестве пролекарств для лечения опухолевых или аутоиммунных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |